<DOC>
	<DOCNO>NCT02473445</DOCNO>
	<brief_summary>A long-term extension study patient mitochondrial disease , ≥ 6 year old &lt; 18 year previously enrol RP103-MITO-001 ( NCT02023866 ) study assess safety , tolerability efficacy RP103 .</brief_summary>
	<brief_title>A Long-Term Extension Study RP103-MITO-001 ( NCT02023866 ) Assess RP103 Children With Inherited Mitochondrial Disease</brief_title>
	<detailed_description>Patients either document genetically confirm diagnosis inherit mitochondrial disease , ≥ 6 year old &lt; 18 year , meet specified inclusion exclusion criterion , include study . Patients inherited mitochondrial disease associate nuclear mitochondrial DNA mutation impair respiratory chain . These include , limited follow clinical syndrome : Leber 's hereditary optic neuropathy ; myoclonic epilepsy ragged-red fiber ( MERFF ) ; mitochondrial encephalomyopathy , lactic acidosis , stroke-like syndrome ( MELAS ) ; Kearn-Sayre syndrome ; subacute necrotizing encephalopathy ( Leigh Syndrome ) ; POLG-related disorder ( Alpers-Huttenlocher Syndrome , Autosomal Dominant Progressive External Ophthalmoplegia , Autosomal Recessive Progressive External Ophthalmoplegia , Childhood Myocerebrohepatopathy Spectrum Disorders , Myoclonic Epilepsy Myopathy Sensory Ataxia , POLG-Related Ataxia Neuropathy Spectrum Disorders ) ; Mitochondrial neurogastrointestinal encephalopathy syndrome ( MNGIE ) , also call myoneurogastrointestinal encephalopathy syndrome POLIP syndrome ; others , e.g. , mitochondrial cardiomyopathy syndrome due multiple mitochondrial DNA deletion . Patients complete RP103-MITO-001 ( NCT02023866 ) study eligible enrollment extension study RP103-MITO-002 inclusion exclusion criterion fulfil . Subjects continue last total daily dose RP103 take RP103-MITO-001 . Dose-adjustments permitted.The sample size maximally 25 subject .</detailed_description>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>1 . Completed visit Study RP103MITO001 ( NCT02023866 ) . 2 . Body weight ≥ 5 kg . 3 . The subject must willing abstain initiating dietary supplement nonprescribed medication except allow Investigator , throughout study ( Day 1 Study Exit ) . 4 . Willing able comply study drug dosing requirement , i.e . ingest RP103 capsule intact , sprinkle liquid soft food , use Gtube . 5 . Sexually active female subject childbearing potential ( i.e. , surgically sterile [ tubal ligation , hysterectomy , bilateral oophorectomy ] ) must agree utilize two follow acceptable form contraception throughout study ( Day 1 Study Exit ) : Hormonal contraception : birth control pill , injection , patch , vaginal ring implant ; Condom diaphragm , spermicide ; Intrauterine device ( IUD ) ; Sterile male partner ( vasectomy perform least 6 month prior study ) . 6 . Patient 's legally authorize representative must provide write informed consent ; Patient must provide assent , require local/institutional requirement . 1 . Documented diagnosis concurrent inborn error metabolism . 2 . Platelet count , lymphocyte count hemoglobin lower limit normal ( LLN ) Baseline visit . 3 . Hepatic insufficiency liver enzyme test ( alkaline phosphatase , AST ALT ) great 2.5 time upper limit normal ( ULN ) Baseline Visit . 4 . Bilirubin &gt; 1.2 g/dL Baseline Visit . 5 . Inability complete element study , e.g. , coma , hemodynamic instability require continuous ventilator support . 6 . Malabsorption require TPN , chronic diarrhea , bouts pseudo obstruction . 7 . Severe endorgan hypoperfusion syndrome secondary cardiac failure result lactic acidosis . 8 . Patients suspect elevated intracranial pressure , pseudotumor cerebri ( PTC ) and/or papilledema . 9 . Severe gastrointestinal disease include gastroparesis . 10 . History drug alcohol abuse . 11 . History pancreatitis . 12 . Participated investigational drug trial ( except RP103MITO001 study ) within 30 day , within 90 day biologic , device , surgical treatment , inherit mitochondrial disease prior Baseline Visit . 13 . Known suspected hypersensitivity cysteamine penicillamine . 14 . Female subject nursing , plan pregnancy , know suspected pregnant , positive serum pregnancy test Baseline visit . 15 . Patients , opinion Investigator , able willing comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>inherit mitochondrial disease</keyword>
	<keyword>Leigh Syndrome</keyword>
	<keyword>LHON</keyword>
	<keyword>MERFF</keyword>
	<keyword>MELAS</keyword>
	<keyword>Kearn-Sayre syndrome</keyword>
	<keyword>POLG-related disorder</keyword>
	<keyword>MNGIE</keyword>
</DOC>